APAC Pharmacogenetics Testing in PsychiatryDepression Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143176
- Pages: 225
-
Format:
Short Description
Asia-Pacific Pharmacogenetics Testing in Psychiatry/Depression Market, By Type (Anxiety, Mood Disorders, Depression, Bipolar Disorders, Psychotic Disorders, and Eating Disorders), Test Type (Whole Genome Sequencing, and Chromosomal Array-Based Tests), Patient Type (Childrens, Adults, and Geriatric), Gene Type (CYP2C19, CYP2C9, VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT, and Others), Products (Instruments, Consumables, Software & Services), End User (Hospitals and Clinics, Diagnostics Laboratories, Academic and Research Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distribution Hospital Pharmacy, and Others), Countries (China, Japan, India, South Korea, Singapore, Thailand, Malaysia, Australia, Vietnam, Philippines, Indonesia, and Rest of the Asia-Pacific) - Industry Trends and Forecast to 2029
Market Definition
Pharmacogenomic testing has recently become scalable and available to guide major depressive disorder (MDD). Clinicians increasingly recognize Pharmacogenomic (PGx) testing as an essential tool to guide medication decisions for psychiatric illnesses. Extensive implementation of PGx testing is driving the market in the forecast period.
Pharmacogenetics testing studies the interaction between the drug and the gene response of a person and searches for the gene variation, which is responsible for influencing the drug effect. The test is gaining high demand as many researchers and scientists identified the unique interaction between drugs and individuals genes and provided valuable insights which subsequently be used to develop customized or personalized medication.
Market Segmentation
The Asia-Pacific pharmacogenetics testing in psychiatry/depression market is categorized into seven notable segments, which are the type, test type, product type, gene type, patient type, end user, and distribution channel.
On the basis of type, the pharmacogenetics testing in psychiatry/depression market is segmented into anxiety, mood disorders, depression, bipolar disorders, psychotic disorders, and eating disorders
On the basis of test type, the pharmacogenetics testing in psychiatry/depression market is segmented into whole genome sequencing, and chromosomal array-based tests
On the basis of patient type, the pharmacogenetics testing in psychiatry/depression market is segmented into children, adults, and geriatrics
On the basis of product type, the pharmacogenetics testing in psychiatry/depression market is segmented into instruments, consumables, and software & services
On the basis of gene type, the pharmacogenetics testing in psychiatry/depression market is segmented into CYP2C19, CYP2C9, VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT, and others
On the basis of end user, the pharmacogenetics testing in psychiatry/depression market is segmented into hospitals and clinics, diagnostics laboratories, academic and research institutes, and others
On the basis of distribution channel, the pharmacogenetics testing in psychiatry/depression market is segmented into direct tender, third-party distribution hospital pharmacy, and others
Market Players
Some of the major players operating in the Asia-Pacific pharmacogenetics testing in psychiatry/depression market are:
Genewiz (Part of Azenta Life Sciences)
PacBio
QIAGEN
Thermo Fisher Scientific Inc.
AB BIOTICS.S.A.
Eurofins Scientific
Illumina, Inc.
STADAPHARM GmbH
Genomind, Inc.
myDNA Life Australia Pty Ltd.
Sonic Healthcare Limited
TABLE OF CONTENTS
1 INTRODUCTION 63
1.1 OBJECTIVES OF THE STUDY 63
1.2 MARKET DEFINITION 63
1.3 OVERVIEW OF ASIA PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET 63
1.4 CURRENCY AND PRICING 65
1.5 LIMITATIONS 66
1.6 MARKETS COVERED 66
2 MARKET SEGMENTATION 70
2.1 MARKETS COVERED 70
2.2 GEOGRAPHICAL SCOPE 71
2.3 YEARS CONSIDERED FOR THE STUDY 72
2.4 DBMR TRIPOD DATA VALIDATION MODEL 73
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 76
2.6 MULTIVARIATE MODELLING 77
2.7 MARKET APPLICATION COVERAGE GRID 78
2.8 SOURCE LIFELINE CURVE 78
2.9 DBMR MARKET POSITION GRID 80
2.10 VENDOR SHARE ANALYSIS 81
2.11 SECONDARY SOURCES 82
2.12 ASSUMPTIONS 82
3 EXECUTIVE SUMMARY 83
3.1 PESTEL ANALYSIS 87
3.2 PORTER'S FIVE FORCES MODEL 88
3.3 INDUSTRIAL INSIGHTS: 89
3.4 PIPELINE ANALYSIS FOR ASIA PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET 91
3.5 EPIDEMIOLOGY 92
4 ASIA PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, REGULATIONS 93
4.1 UNITED STATES (U.S.) 93
4.1.1 ROLE OF FDA 93
4.1.2 ROLE OF CDC AND HCFA 93
4.2 EUROPEAN UNION (EU) 94
4.3 FRANCE 94
4.4 AUSTRALIA 94
4.5 SOUTH KOREA 94
5 MARKET OVERVIEW 95
5.1 DRIVERS 97
5.1.1 INCREASE IN THE NUMBER OF PATIENTS SUFFERING FROM PSYCHIATRIC AND DEPRESSION DISORDER 97
5.1.2 RISE IN HEALTHCARE EXPENDITURE 97
5.1.3 RISE IN DEMAND FOR PERSONALIZED AND PRECISION MEDICINE 98
5.2 RESTRAINTS 98
5.2.1 LACK OF SKILLED MEDICAL AND GENOMIC EXPERT 98
5.2.2 LACK OF STRONG CLINICAL EVIDENCE 99
5.2.3 HIGH COST ASSOCIATED WITH THE DIAGNOSIS 99
5.3 OPPORTUNITIES 99
5.3.1 RISING ADVANCEMENTS IN TECHNOLOGY 99
5.3.2 INCREASING NUMBER OF KEY PLAYERS IN MARKET 100
5.4 CHALLENGES 100
5.4.1 STRICT GOVERNMENT REGULATION ON NEW PRODUCTS AND INSTRUMENTS APPROVAL 100
5.4.2 DEARTH OF SKILLED PERSONNEL 101
6 ASIA PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE 102
6.1 OVERVIEW 103
6.2 ANXIETY 106
6.3 DEPRESSION 106
6.4 MOOD DISORDERS 107
6.5 BIPOLAR DISORDERS 108
6.6 EATING DISORDERS 109
6.7 PSYCHOTIC DISORDERS 109
7 ASIA PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT 111
7.1 OVERVIEW 112
7.2 CONSUMABLES 115
7.2.1 WHOLE GENOME SEQUENCING KITS 116
7.2.2 CHROMOSOMAL ARRAY BASED KITS 116
7.3 INSTRUMENTS 117
7.4 SOFTWARE AND SERVICES 117
8 ASIA PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE 119
8.1 OVERVIEW 120
8.2 WHOLE GENOME SEQUENCING 123
8.2.1 EXOME SEQUENCING 124
8.2.1.1 SNP 125
8.2.1.2 CNV 125
8.2.1.3 RARE PTV MUTATION 125
8.2.1.4 ULTRA PTV MUTATION 125
8.2.1.5 OTHERS 125
8.2.2 KARYOTYPE 125
8.2.2.1 SNP 126
8.2.2.2 CNV 126
8.2.2.3 RARE PTV MUTATION 126
8.2.2.4 ULTRA PTV MUTATION 126
8.2.2.5 OTHERS 126
8.2.3 LOW COVERAGE WGS 126
8.2.3.1 SNP 127
8.2.3.2 CNV 127
8.2.3.3 RARE PTV MUTATION 127
8.2.3.4 ULTRA PTV MUTATION 127
8.2.3.5 OTHERS 127
8.2.4 DEEP COVERAGE WGS 127
8.2.4.1 SNP 128
8.2.4.2 CNV 128
8.2.4.3 RARE PTV MUTATION 128
8.2.4.4 ULTRA PTV MUTATION 128
8.2.4.5 OTHERS 128
8.2.5 MICROARRAY 128
8.2.5.1 SNP 129
8.2.5.2 CNV 129
8.2.5.3 RARE PTV MUTATION 129
8.2.5.4 ULTRA PTV MUTATION 129
8.2.5.5 OTHERS 129
8.2.6 OTHERS 129
8.3 CHROMOSOMAL ARRAY BASED TESTS 129
8.3.1 MICRODELETIONS 130
8.3.2 MICRO DUPLICATIONS 130
9 ASIA PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE 131
9.1 OVERVIEW 132
9.2 CYP2C19 135
9.3 CYP2C9 AND VKORC1 135
9.4 CYP2D6 136
9.5 HLA-B 137
9.6 HTR2A/C 137
9.7 HLA-A 138
9.8 CYP3A4 139
9.9 SLC6A4 139
9.10 MTHFR 140
9.11 COMT 141
9.12 OTHERS 141
10 ASIA PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE 143
10.1 OVERVIEW 144
10.2 ADULT 147
10.3 GERIATRIC 147
10.4 CHILD 148
11 ASIA PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET , BY END USER 149
11.1 OVERVIEW 150
11.2 HOSPITAL AND CLINICS 153
11.2.1 DRUG EFFECTIVENESS 154
11.2.2 SIDE EFFECTS 154
11.2.3 DOSAGE 154
11.3 DIAGNOSTICS LABORATORIES 154
11.3.1 DRUG EFFECTIVENESS 155
11.3.2 SIDE EFFECTS 155
11.3.3 DOSAGE 155
11.4 ACADEMIC AND RESEARCH INSTITUTES 155
11.4.1 DRUG EFFECTIVENESS 156
11.4.2 SIDE EFFECTS 156
11.4.3 DOSAGE 156
11.5 OTHERS 156
12 ASIA PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL 158
12.1 OVERVIEW 159
12.2 DIRECT TENDER 162
12.3 THIRD PARTY DISTRIBUTION 162
12.4 HOSPITAL PHARMACY 163
12.5 OTHERS 163
13 ASIA PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION 165
13.1 ASIA-PACIFIC 166
13.1.1 JAPAN 178
13.1.2 CHINA 185
13.1.3 SOUTH KOREA 192
13.1.4 INDIA 199
13.1.5 AUSTRALIA 206
13.1.6 SINGAPORE 213
13.1.7 THAILAND 220
13.1.8 MALAYSIA 227
13.1.9 INDONESIA 234
13.1.10 PHILIPPINES 241
13.1.11 VIETNAM 248
13.1.12 REST OF ASIA-PACIFIC 255
14 ASIA PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY LANDSCAPE 256
14.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 256
15 SWOT ANALYSIS 257
16 COMPANY PROFILE 258
16.1 THERMO FISHER SCIENTIFIC INC. 258
16.1.1 COMPANY SNAPSHOT 258
16.1.2 RECENT FINANCIALS 258
16.1.3 COMPANY SHARE ANALYSIS 259
16.1.4 PRODUCT PORTFOLIO 259
16.1.5 RECENT DEVELOPMENT 260
16.2 ILLUMINA, INC. 261
16.2.1 COMPANY SNAPSHOT 261
16.2.2 REVENUE ANALYSIS 261
16.2.3 COMPANY SHARE ANALYSIS 262
16.2.4 PRODUCT PORTFOLIO 262
16.2.5 RECENT DEVELOPMENTS 263
16.3 MYRIAD GENETICS, INC. 265
16.3.1 COMPANY SNAPSHOT 265
16.3.2 COMPANY SHARE ANALYSIS 265
16.3.3 PRODUCT PORTFOLIO 266
16.3.4 RECENT DEVELOPMENT 266
16.4 SONIC HEALTHCARE LIMITED 267
16.4.1 COMPANY SNAPSHOT 267
16.4.2 REVENUE ANALYSIS 267
16.4.3 COMPANY SHARE ANALYSIS 268
16.4.4 PRODUCT PORTFOLIO 268
16.4.5 RECENT DEVELOPMENTS 268
16.5 QIAGEN 269
16.5.1 COMPANY SNAPSHOT 269
16.5.2 RECENT FINANCIALS 269
16.5.3 COMPANY SHARE ANALYSIS 270
16.5.4 PRODUCT PORTFOLIO 270
16.5.5 RECENT DEVELOPMENTS 271
16.6 EUROFINS SCIENTIFIC 272
16.6.1 COMPANY SNAPSHOT 272
16.6.2 REVENUE ANALYSIS 272
16.6.3 PRODUCT PORTFOLIO 273
16.6.4 RECENT DEVELOPMENT 273
16.7 AB-BIOTICS, S.A. 274
16.7.1 COMPANY SNAPSHOT 274
16.7.2 PRODUCT PORTFOLIO 274
16.7.3 RECENT DEVELOPMENTS 274
16.8 BIOGENIQ INC. 276
16.8.1 COMPANY SNAPSHOT 276
16.8.2 PRODUCT PORTFOLIO 276
16.8.3 RECENT DEVELOPMENT 276
16.9 CASTLE BIOSCIENCE, INC. 277
16.9.1 COMPANY SNAPSHOT 277
16.9.2 REVENUE ANALYSIS 277
16.9.3 PRODUCT PORTFOLIO 278
16.9.4 RECENT DEVELOPMENT 278
16.10 CNSDOSE 279
16.10.1 COMPANY SNAPSHOT 279
16.10.2 PRODUCT PORTFOLIO 279
16.10.3 RECENT DEVELOPMENT 279
16.11 COLOR HEALTH, INC. 280
16.11.1 COMPANY SNAPSHOT 280
16.11.2 PRODUCT PORTFOLIO 280
16.11.3 RECENT DEVELOPMENTS 281
16.12 CORIELL LIFE SCIENCES 282
16.12.1 COMPANY SNAPSHOT 282
16.12.2 PRODUCT PORTFOLIO 282
16.12.3 RECENT DEVELOPMENTS 282
16.13 DYNAMIC DNA LABORATORIES 285
16.13.1 COMPANY SNAPSHOT 285
16.13.2 PRODUCT PORTFOLIO 285
16.13.3 RECENT DEVELOPMENTS 285
16.14 GENELEX (SUBSIADIARY OF INVITAE CORPORATION.) 287
16.14.1 COMPANY SNAPSHOT 287
16.14.2 REVENUE ANALYSIS 287
16.14.3 PRODUCT PORTFOLIO 288
16.14.4 RECENT DEVELOPMENT 288
16.15 GENEWIZ (PART OF AZENTA LIFE SCIENCES) 289
16.15.1 COMPANY SNAPSHOT 289
16.15.2 REVENUE ANALYSIS 289
16.15.3 PRODUCT PORTFOLIO 290
16.15.4 RECENT DEVELOPMENTS 290
16.16 GENOMIND, INC. 291
16.16.1 COMPANY SNAPSHOT 291
16.16.2 PRODUCT PORTFOLIO 291
16.16.3 RECENT DEVELOPMENTS 291
16.17 GENXYS 293
16.17.1 COMPANY SNAPSHOT 293
16.17.2 PRODUCT PORTFOLIO 293
16.17.3 RECENT DEVELOPMENTS 293
16.18 HEALTHSPEK 295
16.18.1 COMPANY SNAPSHOT 295
16.18.2 PRODUCT PORTFOLIO 295
16.18.3 RECENT DEVELOPMENTS 295
16.19 HUDSONALPHA 296
16.19.1 COMPANY SNAPSHOT 296
16.19.2 PRODUCT PORTFOLIO 296
16.19.3 RECENT DEVELOPMENT 296
16.20 MD LABS 297
16.20.1 COMPANY SNAPSHOT 297
16.20.2 PRODUCT PORTFOLIO 297
16.20.3 RECENT DEVELOPMENTS 297
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
